Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States

Journal of the National Cancer Institute

Volumn 108, Issue 1, 2016, Pages

  Brisson, Marc ^a,b,c   Laprise, Jean François ^a   Chesson, Harrell W ^d   Drolet, Melanie ^a,b   Malagón, Taliá ^a,b   Boily, Marie Claude ^c   Markowitz, Lauri E ^d  

^a University Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE;

ARTICLE; CONTROLLED STUDY; COST CONTROL; CROSS PROTECTION; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGRAM COST EFFECTIVENESS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; UNITED STATES; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; WART VIRUS; ADOLESCENT; ADULT; CHILD; COMPLICATION; COST BENEFIT ANALYSIS; DISEASE TRANSMISSION; ECONOMICS; MASS IMMUNIZATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PREVENTION AND CONTROL; SEXUAL BEHAVIOR; STATISTICAL MODEL; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; COST SAVINGS; COST-BENEFIT ANALYSIS; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; MALE; MASS VACCINATION; MODELS, STATISTICAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; SEXUAL BEHAVIOR; UNITED STATES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84956576274     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv282     Document Type: Article

References (61)

1. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56 (No. RR-2).
2. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent human papillomavirus vaccine in males-Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1705-1708.
3. Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer. 2003;89(1):101-105.
4. Hariri S, Unger ER, Schafer S, et al. HPV type attribution in high grade cervical lesions: assessing the potential benefits of vaccines in a populationbased evaluation in the United States. Cancer Epidemiol Biomarkers Prev. 2015;24(2):393-399.
5. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
6. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7(1):38.
7. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124(7):1626-1636.
8. Saraiya M, Unger E, Thompson T, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107(6):djv086 doi:10.1093/jnci/djv086.
9. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805-814.
10. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
11. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927.
12. Chesson HW, Ekwueme DU, Saraiya M, et al. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States. Vaccine. 2012;30(42):6016-6019.
13. Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)-Associated Cancers and HPV Vaccination Coverage Levels. J Natl Cancer Inst. 2013;105(3):175-201.
14. Chesson HW, Ekwueme DU, Saraiya M, et al. The cost-effectiveness of male HPV vaccination in the United States. Vaccine. 2011;29(46):8443-8450.
15. Chesson HW, Ekwueme DU, Saraiya M, et al. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244-251.
16. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8):821-832.
17. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884.
18. Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine. 2010;28(42):6858-6867.
19. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis. 2007;13(1):28-41.
20. Jit M, Brisson M, Portnoy A, et al. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet. Global Health 2014;2:e406-e414.
21. Merck. FDA Accepts for Review Merck's Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine. 2014. http://www.mercknewsroom.com/news-release/research-and-developmentnews/fda-accepts-review-mercks-biologics-license-application-v. Accessed November 2014.
22. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-723.
23. Van Damme P, Vesikari T, Brodszki N, et al. Immunogenicity and safety of a novel 9-valent vaccine in girls 9-15 years of age compared to the quadrivalent vaccine. Abstract presented at the Eurogin 2013 International Congress. Florence, November 3-6, 2013.
24. Olsson SE, Van Damme P, Herrera T, et al. Immunogenicity and safety of a novel 9-valent HPV L1 virus-like particle vaccine in boys and girls 9-15 years old, comparison to women 16-26 years old. Abstract presented at the 29th International Papillomavirus Conference and Public Health & Clinical Workshops. Seattle, August 21-25, 2014.
25. Advisory Committee on Immunization Practices (ACIP). Meeting of the Advisory Committee on Immunization Practices (ACIP)-Summary Report. Atlanta, Centers for Disease Control and prevention (CDC), October 29-30, 2014.
26. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep. 2014;63(29):620-624.
27. Bureau of Labor Statistics, Labor USDo. Consumer Price Index. Item Medical Care. Series CUUR0000SAM. http://data.bls.gov/timeseries/CUUR0000SAMinclude-graphs=false&output-type=column&years-option=all-years. Accessed November 2013.
28. Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst. 2012;104(22):1712-1723.
29. Brisson M, Laprise JF, Drolet M, et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmissiondynamic modeling study. Vaccine. 2013;31(37):3863-3871.
30. Drolet M, Laprise JF, Boily MC, et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer. 2014;134(9):2264-2268.
31. Centers for Disease Control and Prevention (CDC). Cervical Cancer Screening Among Women Aged 18-30 Years-United States, 2000-2010. http://www. cdc.gov/mmwr/preview/mmwrhtml/mm6151a2.htm. Accessed July 2014.
32. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16(3):175-204.
33. Centers for Disease Control and Prevention. National Survey of Family Growth (NSFG 2006-2010). http://www.cdc.gov/nchs/nsfg.htm. Accessed November 2013.
34. Haderxhanaj LT, Leichliter JS, Aral SO, et al. Sex in a lifetime: Sexual behaviors in the United States by lifetime number of sex partners, 2006-2010. Sex Transm Dis. 2014;41(6):345-352.
35. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey (NHANES). http://www.cdc.gov/nchs/nhanes.htm. Accessed November 2013.
36. Wheeler CM, Hunt WC, Cuzick J, et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132(1):198-207.
37. Hoy T, Singhal PK, Willey VJ, et al. Assessing incidence and economic burden of genital warts with data from a US commercially insured population. Curr Med Res Opin. 2009;25(10):2343-2351.
38. Centers for Disease Control and Prevention, National Cancer Institute. Centers for Disease Control and Prevention's National Program of Cancer Registries and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program.
39. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191(1):105-113.
40. Watson M, Saraiya M, Benard V, et al. Burden of cervical cancer in the United States, 1998-2003. Cancer. 2008;113(10 Suppl):2855-2864.
41. Camenga DR, Dunne EF, Desai MM, et al. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis. 2013;40(7):534-538.
42. Drolet M, Brisson M, Maunsell E, et al. The impact of anogenital warts on health-related quality of life: a 6-month prospective study. Sex Transm Dis. 2011;38(10):949-956.
43. Woodhall S, Ramsey T, Cai C, et al. Estimation of the impact of genital warts on health-related quality of life. Sex Transm Infect. 2008;84(3):161-166.
44. Drolet M, Brisson M, Maunsell E, et al. The psychosocial impact of an abnormal cervical smear result. Psychooncology. 2012;21(10):1071-1081.
45. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36(11):1397-1403.
46. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):500 e1-e7.
47. Schabert VF, Ye X, Insinga RP, et al. Five-year routine cervical cancer screening rates and intervals in a US health plan. Curr Med Res Opin. 2008;24(9):2429-2435.
48. Henk HJ, Insinga RP, Singhal PK, et al. Incidence and costs of cervical intraepithelial neoplasia in a US commercially insured population. J Low Genit Tract Dis. 2010;14(1):29-36.
49. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol. 2004;191(1):114-120.
50. Weiss T, Pillsbury M, Dasbach EJ. Potential health and economic impact of the 9-valent HPV vaccine in the United States. Abstract presented at the 29th International Papillomavirus Conference and Public Health & Clinical Workshops. Seattle, United Stated, August 21-25 2014.
51. Malagon T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(10):781-789.
52. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011;103(19):1444-1451.
53. Dobson SR, McNeil S, Dionne M, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793-1802.
54. Herweijer E, Leval A, Ploner A, et al. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA. 2014;311(6):597-603.
55. Laprise JF, Drolet M, Boily MC, et al. Comparing the cost-effectiveness of twoand three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine. 2014;32(44):5845-5853.
56. Jit M, Brisson M, Laprise J, et al. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ. 2015;350:g7584.
57. World Health Organization. Summary of the SAGE April 2014 meeting. http://www.who.int/immunization/sage/meetings/2014/april/report-summary-april-2014/en/. Accessed November 2014.
58. National Institute of Health. A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010). http://clinicaltrials.gov/show/NCT01984697. Accessed November 2014.
59. Statistics Canada. Canadian Community Health Survey (CCHS-Cycle 3.1).www.statcan.gc.ca. Accessed November 2014.
60. Wellings K, Collumbien M, Slaymaker E, et al. Sexual behaviour in context: a global perspective. Lancet. 2006;368(9548):1706-1728.
61. Campos NG, Burger EA, Sy S, et al. An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol. 2014;180(5):545-555.